Mr Fawaz Alenazy

Birmingham (United Kingdom of Great Britain & Northern Ireland)

Follow

Contributor content

GPVI inhibition by glenzocimab synergistically inhibits atherosclerotic plaque-induced platelet activation when combined with conventional dual antiplatelet therapy

Presentation

GPVI inhibition by glenzocimab synergistically inhibits atherosclerotic plaque-induced platelet activation when combined with conventional dual antiplatelet therapy

ESC 365 is supported by

novartis

Explore sponsored resources